Medicare Enrolled

Dr. Jamie Koprivnikar, M.D.

Hematology · Hackensack, NJ
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
92 2ND ST, Hackensack, NJ 07601
5519963925
In practice since 2008 (18 years)
NPI: 1295994614 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Koprivnikar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Koprivnikar? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Koprivnikar

Dr. Jamie Koprivnikar is a hematology specialist in Hackensack, NJ, with 18 years of NPI registration. Based on federal Medicare data, Dr. Koprivnikar performed 13,609 Medicare services across 830 unique beneficiaries.

Between the years covered by Open Payments, Dr. Koprivnikar received a total of $1,366,274 from 39 pharmaceutical and/or device companies across 1366 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Koprivnikar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice ▲ Top 24% volume in NJ $1,366,274 industry payments

Medicare Practice Summary

Medicare Utilization ↗
13,609
Medicare services
Top 24% in NJ for hematology
830
Unique beneficiaries
$23
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~756 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Epoetin alfa injection (Procrit) for anemia
An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis.
11,200 $6 $40
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
673 $107 $238
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
538 $151 $301
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
357 $75 $154
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
348 $101 $220
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
240 $12 $75
Bone marrow smear interpretation
A laboratory review of a bone marrow sample slide to examine cell structure and identify abnormalities.
57 $60 $300
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
48 $142 $423
Bone marrow aspiration
A procedure to remove a small sample of liquid bone marrow for diagnostic testing.
44 $69 $598
Biopsy of bone marrow 44 $143 $644
Hospital discharge day management, 30 minutes or less
This service covers the final day of hospital care when the patient is being discharged. It includes coordination of care and instructions for the patient within a time frame of 30 minutes or less.
34 $66 $177
New patient office visit, complex (60-74 min) 26 $170 $463
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$1,366,274
Total received (2018-2024)
Avg $195,182/year across 7 years
Top 2% in NJ for hematology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
39
Companies
1,366
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,241,851 (90.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$116,222 (8.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,202 (0.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$416,085
2023
$327,484
2022
$227,295
2021
$89,558
2020
$68,584
2019
$101,316
2018
$135,952

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
SOBI, INC
$108,719
Alexion Pharmaceuticals, Inc.
$107,247
E.R. Squibb & Sons, L.L.C.
$79,585
Astellas Pharma US Inc
$40,601
Novartis Pharmaceuticals Corporation
$22,283
Apellis Pharmaceuticals, Inc.
$12,649
GlaxoSmithKline, LLC.
$9,420
Amgen Inc.
$8,685
Geron Corporation
$5,137
PharmaEssentia USA Corporation
$4,328
GENZYME CORPORATION
$3,464
Rigel Pharmaceuticals, Inc.
$3,428
Incyte Corporation
$3,354
ABBVIE INC.
$3,147
TAIHO ONCOLOGY, INC.
$2,783
Celgene Corporation
$1,054
Blueprint Medicines Corporation
$100
Daiichi Sankyo Inc.
$47
Takeda Pharmaceuticals U.S.A., Inc.
$23
Genentech USA, Inc.
$16
Adaptive Biotechnologies Corporation
$15
Top 3 companies account for 71.0% of 2024 payments
All-time payments by company (2018-2024) ›
Alexion Pharmaceuticals, Inc.
$450,782
E.R. Squibb & Sons, L.L.C.
$238,448
Amgen Inc.
$118,909
SOBI, INC
$108,719
CTI BioPharma Corp.
$88,202
Apellis Pharmaceuticals, Inc.
$55,647
Novartis Pharmaceuticals Corporation
$55,188
Astellas Pharma US Inc
$41,393
Celgene Corporation
$40,853
NOVARTIS PHARMACEUTICALS CORPORATION
$34,458
AbbVie, Inc.
$28,749
ABBVIE INC.
$24,469
GlaxoSmithKline, LLC.
$16,398
PharmaEssentia USA Corporation
$10,207
JAZZ PHARMACEUTICALS INC.
$9,345
AbbVie Inc.
$8,894
Jazz Pharmaceuticals Inc.
$7,493
Geron Corporation
$5,137
PFIZER INC.
$3,586
GENZYME CORPORATION
$3,491
Rigel Pharmaceuticals, Inc.
$3,462
Incyte Corporation
$3,406
Otsuka America Pharmaceutical, Inc.
$3,121
TAIHO ONCOLOGY, INC.
$2,799
Partner Therapeutics, Inc.
$2,105
Servier Pharmaceuticals LLC
$271
Daiichi Sankyo Inc.
$227
Blueprint Medicines Corporation
$100
Cardinal Health 110 LLC
$100
Janssen Biotech, Inc.
$70
Takeda Pharmaceuticals U.S.A., Inc.
$69
Gilead Sciences, Inc.
$50
Stemline Therapeutics Inc.
$42
Genentech USA, Inc.
$16
Merck Sharp & Dohme Corporation
$15
Adaptive Biotechnologies Corporation
$15
Pharmacyclics LLC, An AbbVie Company
$14
Agios Pharmaceuticals, Inc.
$13
Foundation Medicine, Inc.
$12
Top 3 companies account for 59.1% of all-time payments
Associated products mentioned in payments ›
AYVAKIT · BESREMI · BOSULIF · Blincyto · DARZALEX · ELITEK · ELZONRIS · EMPAVELI · EPKINLY · Empaveli · FOUNDATIONONE · Fabhalta · GLEEVEC · ICLUSIG · IDHIFA · INJECTAFER · INQOVI · INREBIC · Idhifa · Inrebic · JADENU · JAKAFI · LONSURF · Leukine · MYLOTARG · NINLARO · NOXAFIL · OJJAARA · ONUREG · PLUVICTO · PROMACTA · REBLOZYL · RYDAPT · RYLAZE · RYTELO · Revlimid · Rezlidhia · SCEMBLIX · SOLIRIS · SPRYCEL · TASIGNA · TIBSOVO · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · ULTOMIRIS · Ultomiris · VENCLEXTA · VONJO · VYXEOS · Vanflyta · Venclexta · Vonjo · XOSPATA · Xospata · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (91%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for hematology in NJ.

Looking for a hematology specialist in Hackensack?
Compare hematologists in the Hackensack area by procedure volume, costs, and industry payment transparency.
Browse hematologists nearby

Geographic Context

Hematologists within 10 mi
132
Per 100K population
13.8
County median income
$123,715
Nearest hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Koprivnikar is a mixed practice specialist, with above-average Medicare volume (top 24% in NJ), with speaking/promotional industry engagement in the top 2% of NJ peers, with 18 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Koprivnikar experienced with epoetin alfa injection (procrit) for anemia?
Based on Medicare claims data, Dr. Koprivnikar performed 11,200 epoetin alfa injection (procrit) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Koprivnikar receive payments from pharmaceutical companies?
Yes. Dr. Koprivnikar received a total of $1,366,274 from 39 companies across 1,366 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Koprivnikar's costs compare to other hematologists in Hackensack?
Dr. Koprivnikar's average Medicare payment per service is $23. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Koprivnikar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →